Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H25FN4O2 |
| Molecular Weight | 420.4793 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=CN2C(=O)C(CCN3CCC(CC3)C4=NOC5=C4C=CC(F)=C5)=C(C)N=C12
InChI
InChIKey=ZZQNEJILGNNOEP-UHFFFAOYSA-N
InChI=1S/C24H25FN4O2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17H,7-9,11-13H2,1-2H3
| Molecular Formula | C24H25FN4O2 |
| Molecular Weight | 420.4793 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Ocaperidone [R 79598] is an equipotent antagonist of central dopamine D2 and serotonin2 receptors being investigated as a potential antipsychotic agent. Ocaperidone is a benzisoxazol piperidine antipsychotic primarily binds and with high affinity to 5-HT2 (serotonin) receptors, alpha1 and alpha 2 adrenergic receptors, dopamine D2 receptors and histamine H1 receptors. Ocaperidone is an antagonist primarily at the 5HT and D2 receptors. A proposed mechanism of action is the central D2 receptor blockade which is common to all neuroleptics that are used to treat positive symptoms of schizophrenia.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11522469 |
9.52 null [pKi] | ||
Target ID: CHEMBL5717 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11522469 |
7.55 null [pKi] | ||
Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11522469 |
8.43 null [pKi] |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. | 1998-04 |
|
| 5-HT1A receptor activates Na+/H+ exchange in CHO-K1 cells through Gialpha2 and Gialpha3. | 1997-03-21 |
|
| Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. | 1996-12 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1370538
Ocaperidone was studied at various time intervals after s.c. (10 ml/kg for rats and 0.5 ml/kg for
dogs), oral (10 ml/kg for mice and rats and 0.5 ml/kg for dogs) or i.v. administration (10 ml/kg for mice, 2 ml/kg for rats and 0.5 ml/kg for dogs).
Route of Administration:
Other
Ocaperidone is an effective antipsychotic agent, acting as a potent 5-HT2 and dopamine D2 antagonist, and a 5-HT1A agonist, with Kis of 0.14 nM, 0.46 nM, 0.75 nM, 1.6 nM and 5.4 nM for 5-HT2, a1-adrenergic receptor, dopamine D2, histamine H1 and a2-adrenergic receptor, respectively, and a pEC50 and pKi of 7.60 and 8.08 for h5-HT1A.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:10:37 GMT 2025
by
admin
on
Mon Mar 31 18:10:37 GMT 2025
|
| Record UNII |
26HUS7139V
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2104619
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
SUB09395MIG
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
100000083610
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
FF-49
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
26HUS7139V
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
Ocaperidone
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
6679
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
71351
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
129029-23-8
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
DB06229
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
DTXSID10156042
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY | |||
|
C76441
Created by
admin on Mon Mar 31 18:10:37 GMT 2025 , Edited by admin on Mon Mar 31 18:10:37 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TARGET -> AGONIST | |||
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |